Spironolactone and PCOS / PMOS — Anti-Androgen for Acne, Hirsutism, Hair Loss

What is spironolactone and why is it used in PCOS?

Spironolactone (brand name: Aldactone, CaroSpir) is a synthetic steroid that was originally developed as an aldosterone antagonist — a diuretic for managing high blood pressure and heart failure. However, because it also competitively blocks androgen receptors in peripheral tissues (skin, hair follicles, sebaceous glands), it became one of the most widely used anti-androgen treatments for women with PCOS.

In PCOS/PMOS, excess androgens drive three of the most distressing symptoms: hormonal acne, hirsutism (male-pattern hair growth on face and body), and female-pattern hair loss (FPHL). Spironolactone addresses all three at the target organ level. Sources: Spritzer PM, meta-analysis 2022; ESHRE 2023 PCOS Guideline.

Dual mechanism of action in PCOS

Spironolactone works through two complementary mechanisms in PCOS:

1. Peripheral androgen receptor blockade

Spironolactone competitively binds to androgen receptors in hair follicles, sebaceous glands, and skin keratinocytes — blocking testosterone and its more potent derivative DHT (dihydrotestosterone) from activating these receptors. The clinical result: reduced sebum production (less acne), reduced hair follicle stimulation by androgens (slower hirsutism progression, partial hair loss reversal).

2. Inhibition of androgen synthesis (at higher doses)

At doses of 100 mg/day and above, spironolactone also inhibits 17α-hydroxylase and 17,20-lyase enzymes in the ovary and adrenal cortex — key enzymes in the androgen biosynthesis pathway. This adds a central anti-androgenic effect on top of the peripheral receptor blockade. Total testosterone reduction of 20–35% is documented at doses of 100–200 mg/day. Sources: Spritzer PM 2022; Brown J, Cochrane 2015.

Scientific evidence — what the data shows

Spironolactone has a substantial evidence base for androgenic symptoms, although randomized controlled trial data in PCOS specifically (as opposed to idiopathic hirsutism) is more limited than for metformin or letrozole:

• Spritzer PM 2022 (meta-analysis, 15 studies): Spironolactone significantly reduced Ferriman-Gallwey (FG) hirsutism scores by a mean of 4–5 points (from baseline scores typically 15–20). Clinical significance: FG reduction >3 points is considered the minimum detectable change by patients.
• Brown J, Cochrane 2015: Compared spironolactone with other anti-androgens for hirsutism and acne. Spironolactone 100–200 mg/day reduced acne lesion counts by 60–80% at 6 months, comparable to flutamide but with a more favorable safety profile (flutamide carries hepatotoxicity risk).
• ESHRE 2023 Guideline: Grade B recommendation for anti-androgen therapy (including spironolactone) for cosmetic hyperandrogenism symptoms when COC alone is insufficient or contraindicated.
• BJD 2024 (British Journal of Dermatology): Prospective study specifically in FPHL associated with PCOS. Spironolactone 100–200 mg/day showed 30–40% improvement in hair density scores (phototrichogram) at 12 months. Strongest response in women with documented androgen excess at baseline.

Evidence level: Grade B for hirsutism and acne (ESHRE 2023, Cochrane 2015); Grade B–C for FPHL (limited RCT data, strong observational evidence). Sources: Spritzer 2022; Brown Cochrane 2015.

Spironolactone molecule profile in PCOS — summary table

Dosing and titration protocol

The optimal dosing approach for PCOS balances anti-androgenic efficacy with tolerability and the hyperkalemia risk:

• Starting dose: 25–50 mg once daily (morning, with food)
• Titration at 4–8 weeks: Increase to 100 mg/day if initial dose tolerated and potassium normal
• Maintenance for acne/hirsutism: 100 mg/day is the most studied effective dose
• FPHL or insufficient response: 150–200 mg/day (split into 2 doses); check K+ more frequently at higher doses

Clinical pearls:

• Always co-prescribe with an effective contraceptive method before the first dose
• Take with food to improve absorption and reduce GI symptoms
• Morning dosing preferred to minimize nocturia from diuretic effect
• Do not combine with high-potassium supplements or salt substitutes (KCl-based)

Mandatory contraception — understanding the teratogenicity risk

This is the most critical safety consideration for spironolactone in women of childbearing age. The risk is well-documented:

In male embryos during the 8th–14th week of gestation, androgens (testosterone and DHT) are essential for masculinization of the external genitalia. Spironolactone, by blocking androgen receptors systemically, can prevent this masculinization, resulting in feminization of male fetuses — a condition called pseudohermaphroditism. Animal studies (rats) demonstrate this consistently at doses proportional to those used clinically. Human case reports corroborate the risk.

Practical requirements:

• Confirm negative pregnancy test before initiating spironolactone
• Use effective contraception throughout treatment — combined oral contraceptive with anti-androgenic progestin (drospirenone or dienogest) is preferred: provides contraception AND adds anti-androgenic benefit
• Stop spironolactone at least 1–3 months before planned conception attempt
• If pregnancy is suspected or confirmed while on spironolactone: stop immediately and contact your physician

Side effects — complete profile

Common side effects (manageable)

• Menstrual irregularity: The most common complaint in women not using COC concurrently. Spironolactone's progesterone-like activity can alter cycle timing. This is why combining with a COC (which regulates cycles) is often preferred.
• Breast tenderness: Dose-dependent; occurs in ~15–20% at doses of 100+ mg/day. Usually mild and resolves over time.
• Increased urinary frequency: Due to diuretic effect. Manageable by morning dosing; usually improves after the first few weeks.
• Postural hypotension: Rare at PCOS doses but can occur in thin women. Rise slowly from lying position; ensure adequate fluid intake.

Serious side effects (monitor for)

• Hyperkalemia: Elevated serum potassium is the primary safety concern. Risk is low in healthy young women with normal renal function at doses ≤100 mg/day, but increases significantly with: renal impairment, concurrent ACE inhibitors or ARBs, NSAIDs, or potassium supplementation. Mandatory K+ check at month 1, month 3, then annually.
• Teratogenicity (male fetus feminization): Described above. Absolute contraindication in pregnancy.

Contraindications — absolute and relative

Absolute contraindications:

• Pregnancy or planned pregnancy (stop ≥1–3 months before conception attempt)
• Hyperkalemia (serum K+ >5.0 mEq/L) at baseline
• Severe renal impairment (eGFR <30 mL/min)
• Addison's disease (adrenal insufficiency — risks adrenal crisis with aldosterone blockade)
• Concurrent use of eplerenone (additive hyperkalemia risk)

Relative contraindications (use with caution and monitoring):

• eGFR 30–60: use at lower doses with frequent K+ monitoring
• Concurrent ACE inhibitors or ARBs: significantly increases hyperkalemia risk; co-management with physician mandatory
• Pre-existing hypotension (SBP <90 mmHg)
• Liver disease: spironolactone is extensively hepatically metabolized

Drug interactions

• ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan): High-risk combination for hyperkalemia. Both drug classes reduce aldosterone, adding to spironolactone's potassium-retaining effect. If combination necessary, very frequent K+ monitoring required.
• NSAIDs (ibuprofen, naproxen): Can impair renal prostaglandin synthesis, reducing GFR and increasing K+ retention. Minimize chronic NSAID use.
• Potassium supplements and salt substitutes (KCl): Additive hyperkalemia risk. Avoid unless specifically prescribed with monitoring.
• Digoxin: Spironolactone interferes with digoxin assays, causing falsely elevated digoxin levels. Clinical relevance only if both drugs used together.
• Combined oral contraceptives: No adverse interaction. COC with drospirenone (which itself has mild anti-mineralocorticoid activity) — the combination with spironolactone theoretically increases hyperkalemia risk slightly; monitor K+.

Monitoring protocol on spironolactone

A structured monitoring schedule ensures safe use in PCOS:

• Before starting: Pregnancy test (negative required); serum K+; creatinine/eGFR; blood pressure
• Month 1: Serum K+; BP; symptom review (menstrual changes, breast tenderness)
• Month 3: Serum K+; creatinine; clinical efficacy review (FG score or acne assessment)
• Every 6–12 months thereafter: Serum K+; creatinine; BP; contraception confirmation

To track your hair loss and skin improvements over time, see our PCOS hair loss guide and review AMH and androgen testing in PCOS.

Cost and insurance coverage (United States)

Spironolactone is available in generic form at low cost:

• Generic spironolactone: $15–30/month at most pharmacies; as low as $7–10/month via GoodRx at discount pharmacies
• CaroSpir (brand oral solution): Significantly more expensive ($200+/month); primarily for patients who cannot swallow tablets

Insurance coverage: Spironolactone is not FDA-approved for PCOS. However, because it is so inexpensive as a generic and widely prescribed for hypertension and heart failure, most insurance plans cover it with a standard prescription — the off-label PCOS indication rarely affects coverage at this price point. Source: GoodRx 2024.

Alternatives when spironolactone is not appropriate

Alternative options depend on the symptom being targeted:

• For acne + hirsutism: Combined oral contraceptive with anti-androgenic progestin (drospirenone, dienogest) as first step before adding spironolactone. See our birth control and PCOS guide.
• For FPHL when fertility is desired: Finasteride (5α-reductase inhibitor) is not recommended in women of childbearing age (teratogenic). Minoxidil topical (FDA-approved for FPHL, 5%) is the alternative.
• For hirsutism when spironolactone contraindicated: Flutamide (more potent, but carries hepatotoxicity risk); eflornithine cream (topical, face only, FDA-approved for unwanted facial hair).

FAQ — Your questions about spironolactone and PCOS

Why do I need contraception while taking spironolactone for PCOS?

Spironolactone is a potent anti-androgen. In male fetuses, androgens are essential for normal genital development. Animal and human case data document feminization of male fetuses when pregnant women were exposed to spironolactone or similar anti-androgens. To prevent this risk, effective contraception is mandatory throughout treatment. A combined oral contraceptive (with anti-androgenic progestin) is typically the preferred choice as it provides both contraception and adds to the anti-androgenic effect.

Does spironolactone raise potassium levels?

Spironolactone blocks aldosterone receptors in the kidney, which can reduce potassium excretion and cause hyperkalemia (high potassium). In healthy young women with normal renal function, this risk is low at PCOS doses (50–100 mg/day). Clinical monitoring: check serum potassium at 1 month, 3 months, then annually. Avoid potassium supplements and excessive potassium-rich foods (banana, avocado) unless specifically advised otherwise. The risk increases significantly with concurrent ACE inhibitors or ARBs.

How long before spironolactone improves acne in PCOS?

Initial improvement in acne is typically visible at 2–3 months. Maximal benefit for hormonal acne requires 6 months of treatment. In PCOS-related hormonal acne specifically, a 2015 Cochrane review found 60–80% reduction in lesion counts at 6 months with doses of 100–200 mg/day. Hirsutism improves more slowly — 6–12 months for significant FG score reduction.

Can spironolactone help with hair loss (FPHL) in PCOS?

Yes. A 2024 study in the British Journal of Dermatology specifically evaluating spironolactone for female-pattern hair loss (FPHL) in PCOS showed 30–40% improvement in hair density scores at 12 months with 100–200 mg/day. Spironolactone is one of the few systemic options for FPHL driven by androgenic excess. Earlier data from Spritzer 2022 (meta-analysis 15 studies) confirmed meaningful reduction in Ferriman-Gallwey scores.

Is spironolactone FDA-approved for PCOS?

No. Spironolactone is FDA-approved for hyperaldosteronism, hypertension, and heart failure. Its use in PCOS (hirsutism, acne, hair loss) is off-label. However, it is widely used in clinical practice, endorsed by ESHRE 2023 (Grade B recommendation for hyperandrogenism symptoms), and considered a first-line agent for hirsutism and hormonal acne in many endocrinology and dermatology guidelines.

How do I stop spironolactone if I want to get pregnant?

Stop spironolactone at least 1–3 months before attempting conception to allow clearance of the drug and normalization of potassium levels. Simultaneously stop the contraceptive method you were using (if it was hormonal, ovulation may take 1–3 months to return). Your physician may consider short-term alternatives for acne management during conception attempts if needed (topical retinoids are also contraindicated — discuss safe options).